Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease-Reference-Cited by-同舟云学术

Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease

Published:2017-09 Issue:5 Volume:43 Page:287-296
ISSN:1542-2321
Container-title:Eye & Contact Lens: Science & Clinical Practice
language:en
Short-container-title:

Author:

Goldstein Michael H.,Martel Joseph R.,Sall Kenneth,Goldberg Damien F.,Abrams Marc,Rubin Jay,Sheppard John,Tauber Joseph,Korenfeld Michael,Agahigian Jennifer,Durham Todd A.,Furfine Eric

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology

Reference20 articles.

1. International dry eye workshop (DEWS) report;Ocul Surf,2007

2. Role of Th17 cells in the immunopathogenesis of dry eye disease;Chauhan;Mucosal Immunol,2009

3. Epithelial-immune cell interaction in dry eye;Pflugfelder;Cornea,2008

4. A clinical perspective of IL-1B as the gatekeeper of inflammation;Dinarello;Eur J Immunol,2011

5. Dry eye disease: An immune-mediated ocular surface disorder;Stevenson;Arch Ophthalmol,2012

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in drug treatments for dry eye disease;Expert Opinion on Pharmacotherapy;2023-10-17

2. 5‐Fluoro/(trifluoromethoxy)‐2‐indolinone derivatives with anti‐interleukin‐1 activity;Archiv der Pharmazie;2023-10-10

3. Efficacy of Interleukin-1β Inhibitor on Dry Eye Disease in Patients with Degenerative Arthritis;Clinical Ophthalmology;2023-10

4. Update on Dry Eye Disease Treatment: Evidence From Randomized Controlled Trials;Eye & Contact Lens: Science & Clinical Practice;2023-09-20

5. The vicious cycle of dry eye disease: a look into promising novel drug therapies;Expert Review of Ophthalmology;2023-07-04